| 000 | 03397 am a22004453u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 100 | 1 | 0 |
_aAsherson, P _eauthor _91771 |
| 700 | 1 | 0 |
_aJohansson, L _eauthor _91772 |
| 700 | 1 | 0 |
_aHolland, R _eauthor _91773 |
| 700 | 1 | 0 |
_aBedding, M _eauthor _91774 |
| 700 | 1 | 0 |
_aForrester, A _eauthor _91775 |
| 700 | 1 | 0 |
_aGiannulli, L _eauthor _91776 |
| 700 | 1 | 0 |
_aGinsberg, Y _eauthor _91777 |
| 700 | 1 | 0 |
_aHowitt, S _eauthor _91778 |
| 700 | 1 | 0 |
_aKretzschmar, I _eauthor _91779 |
| 700 | 1 | 0 |
_aLawrie, SM _eauthor _91780 |
| 700 | 1 | 0 |
_aMarsh, C _eauthor _91781 |
| 700 | 1 | 0 |
_aKelly, C _eauthor _91782 |
| 700 | 1 | 0 |
_aMansfield, M _eauthor _91783 |
| 700 | 1 | 0 |
_aMcCafferty, C _eauthor _91784 |
| 700 | 1 | 0 |
_aKhan, K _eauthor _91785 |
| 700 | 1 | 0 |
_aMuller-Sedgwick, U _eauthor _91786 |
| 700 | 1 | 0 |
_aStrang, J _eauthor _91787 |
| 700 | 1 | 0 |
_aWilliamson, G _eauthor _91788 |
| 700 | 1 | 0 |
_aWilson, L _eauthor _91789 |
| 700 | 1 | 0 |
_aYoung, S _eauthor _91790 |
| 700 | 1 | 0 |
_aLandau, S _eauthor _91791 |
| 700 | 1 | 0 |
_aThomson, L _eauthor _91792 |
| 245 | 0 | 0 | _aRandomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder (CIAO-II) |
| 260 | _c2023-01. | ||
| 500 | _a/pmc/articles/PMC7613969/ | ||
| 500 | _a/pubmed/35657651 | ||
| 520 | _aBACKGROUND: 20-30% of prisoners meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate reduces ADHD symptoms but effects in prisoners are uncertain due to comorbid mental health and substance use disorders. AIM: To estimate the efficacy of an Osmotic-Release-Oral-System methylphenidate (OROS-methylphenidate) in reducing ADHD symptoms in young adult prisoners with ADHD. METHODS: An 8-week parallel arm, double-blind, randomised, placebo-controlled trial of OROS-methylphenidate versus placebo in male prisoners (aged 16-25) meeting DSM-5 criteria for ADHD. Primary outcome was ADHD symptoms at 8-weeks using the investigator rated Connors Adult ADHD Rating Scale (CAARS-O). Thirteen secondary outcome measures included emotional dysregulation, mind-wandering, violent attitudes, mental health symptoms, and prison officer and educational staff ratings of behaviour and aggression. FINDINGS: Mean CAARS-O at 8 weeks in the OROS-methylphenidate arm was estimated to be reduced by 0.57 points relative to the Placebo arm (95% CI: -2.41 to 3.56) and non-significant. The responder rate, defined as a 20% reduction in CAARS-O scores was 48.3% for the OROS-methylphenidate arm and 47.9% for the placebo arm. No statistically significant trial arm differences were detected for any of the secondary outcomes. Mean final titrated dose was 53.8 mg in the OROS-methylphenidate arm. CONCLUSIONS: ADHD symptoms did not respond to OROS-methylphenidate in young adult prisoners. The findings do not support routine treatment with OROS-methylphenidate in this population. Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multimodal treatments, and preventative interventions in the community. TRIAL REGISTRATION: EudraCT Number 2015-004271-78; ISRCTN16827947. Database lock 27(th) August 2019 | ||
| 540 | _a | ||
| 546 | _aen | ||
| 690 | _aArticle | ||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nBr J Psychiatry | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.1192/bjp.2022.77 _zConnect to this object online. |
| 999 |
_c2039 _d2039 |
||